5-Amino-1MQ Evidence Guide
Evidence for 5-Amino-1MQ is too preliminary to support a research protocol with confidence. All published data is from mouse models in a single research group, with no human pharmacokinetic data and no independent replication. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or tesofensine have vastly stronger evidence bases as starting points.
Our Take
Evidence for 5-Amino-1MQ is too preliminary to support a research protocol with confidence. All published data is from mouse models in a single research group, with no human pharmacokinetic data and no independent replication. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or tesofensine have vastly stronger evidence bases as starting points.
- Best for
- NNMT inhibition mechanistic research (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol - animal doses range from 75mg/kg in rodent studies
Benefits and Evidence
- Fat Mass Reduction: Level D, mostly non-human evidence - Significant fat mass reduction in diet-induced obese mice without changes in food intake. Adipocyte size reduced and metabolic activity increased.
- NAD+ and Metabolic Enhancement: Level D, mostly non-human evidence - Increased intracellular NAD+ levels and enhanced sirtuin activity in preclinical models, improving mitochondrial function and cellular energy metabolism.
Side Effects and Warnings
- Limited safety data
- No significant adverse effects reported in preclinical studies
- Potential for off-target methyltransferase inhibition at high doses (theoretical)
- No human clinical trials completed
- Technically a small molecule, not a peptide - regulatory classification differs
- Long-term safety profile unknown
- Quality and purity of commercially available product highly variable
Research Dosage References
- <strong>Oral (animal studies)</strong> - 10-20 mg/kg - Daily - Animal study dosing only. No established human dosing. Some clinics use 50-100 mg oral or subcutaneous, but this is not evidence-based.
Mechanism of Action
NNMT (nicotinamide N-methyltransferase) catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. This reaction depletes both the SAM methylation pool and the NAD+ salvage pathway, as nicotinamide is the primary precursor for NAD+ biosynthesis via the salvage route. 5-Amino-1MQ competitively inhibits NNMT, preventing nicotinamide methylation. This results in increased nicotinamide availability for NAD+ biosynthesis through the salvage pathway involving NAMPT (nicotinamide phosphoribosyltransferase). Elevated NAD+ levels activate sirtuins (particularly SIRT1 and SIRT3) and other NAD+-dependent enzymes that promote mitochondrial function and fatty acid oxidation. In adipose tissue, NNMT inhibition by 5-Amino-1MQ shrinks adipocytes, reduces lipid storage, and promotes a metabolically active phenotype. Preclinical studies in diet-induced obese mice demonstrated significant reductions in body weight and fat mass without changes in food intake, suggesting the effects are mediated through increased energy expenditure rather than appetite suppression.
Legal Status
Not FDA approved. Not scheduled. Available as a research chemical from specialty suppliers.
Primary Sources
- NNMT inhibition as a therapeutic strategy for obesity and metabolic dysfunction. Biochemical Pharmacology, 2018.
- Small molecule NNMT inhibitors reduce adiposity in diet-induced obese mice. Journal of Pharmacology and Experimental Therapeutics, 2017.